P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS

• A. Vannucchi,
• N. Pemmaraju,
• B. Scott,
• M. Savona,
• S. Oh,
• F. Palandri,
• H. K. Al-Ali,
• M. Sobas,
• M. F. McMullin,
• V. Gupta,
• A. Yacoub,
• R. Mesa,
• S. Buckley,
• K. Roman-Torres,
• S. Verstovsek,
• C. Harrison

Affiliations

A. Vannucchi

1 Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

N. Pemmaraju

2 The University of Texas MD Anderson Cancer Center, Houston, TX

B. Scott

3 Fred Hutchinson Cancer Research Center, Seattle, WA

M. Savona

4 Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

S. Oh

5 Washington University School of Medicine, St. Louis, MO, United States of America

F. Palandri

6 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

H. K. Al-Ali

7 Krukenberg Cancer Center, University Hospital Halle, Halle, Germany

M. Sobas

8 Wroclaw Medical University, Wroclaw, Poland

M. F. McMullin

9 Queen’s University Belfast, Belfast, United Kingdom

V. Gupta

10 Princess Margaret Cancer Centre, Toronto, ON, Canada

A. Yacoub

11 The University of Kansas Cancer Center, Kansas City, KS

R. Mesa

12 UT Health San Antonio Cancer Center, San Antonio, TX

S. Buckley

13 CTI BioPharma, Seattle, WA, United States of America

K. Roman-Torres

13 CTI BioPharma, Seattle, WA, United States of America

S. Verstovsek

2 The University of Texas MD Anderson Cancer Center, Houston, TX

C. Harrison

14 Guy’s and St Thomas’ NHS Trust, London, United Kingdom